Report of the 6th meeting on the evaluation of pandemic influenza vaccines in clinical trials World Health Organization, Geneva, Switzerland, 17-18 February 2010

Vaccine

Volumn 28, Issue 42, 2010, Pages 6811-6820

  Girard, Marc P ^a   Katz, Jacqueline ^b   Pervikov, Yuri ^c   Palkonyay, Laszlo ^c   Kieny, Marie Paule ^c  

^a French National Academy of Medicine   (France)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Clinical trials; H1N1 influenza; Influenza vaccines; Pandemic influenza

Indexed keywords

ALUMINUM PHOSPHATE; AREPANRIX; CELTURA; FLUBLOK; FLUVAL; HUMENZA; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; LIVE VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; PANVAX; PAXVAX; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VAXIFLU S;

ABSENCE OF SIDE EFFECTS; ANTIBODY RESPONSE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNOGENICITY; INFLUENZA A (H1N1); INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; NONHUMAN; PANDEMIC INFLUENZA; PRIORITY JOURNAL; SINGLE DRUG DOSE; STANDARDIZATION; SWITZERLAND; UNSPECIFIED SIDE EFFECT; VACCINATION; WORLD HEALTH ORGANIZATION;

ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; CONGRESSES AS TOPIC; HUMANS; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; PANDEMICS; VACCINES, ATTENUATED; VACCINES, INACTIVATED; WORLD HEALTH ORGANIZATION;

EID: 77956871830     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.07.034     Document Type: Conference Paper

References (26)

1. Gatherer D. The 2009 H1N1 influenza outbreak in its historical context. J Clin Virol 2009, 45(3):174-178.
2. Peiris J.S., Poon L.L., Guan Y. Emergence of a novel swine-origin influenza A virus (S-OIV) H1N1 virus in humans. J Clin Virol 2009, 45:169-173.
3. Smith G.J., Vijaykrishna D., Bahl J., Lycett S.J., Worobey M., Pybus O.G., et al. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature 2009, 459:1122-1125.
4. Garten R.J., Davis C.T., Russell C.A., Shu B., Lindstrom S., Balish A., et al. Antigenic and genetic characteristics of swine-origin 2009 A (H1N1) influenza viruses circulating in humans. Science 2009, 325:197-201.
5. Yang Y., Sugimoto J.D., Halloran M.E., Basta N.E., Chao D.L., Matrajt L., et al. The transmissibility and control of pandemic influenza A (H1N1) virus. Science 2009, 326:729-733.
6. Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza, Bautista E., Chotpiotayasunondh T., Gao Z., Harper S.A., Shaw S.A., et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2009, 362:1708-1719.
7. Hayden F.G., Howard W.A., Palkonyay L., Kieny MP Report of the 5th meeting on the evaluation of pandemic influenza prototype vaccines in clinical trials, World Health Organization, Geneva, Switzerland, 12-13 February 2009. Vaccine 2009, 27:4079-4089.
8. Childs R.A., Palma A.S., Wharton S., Mastrosovitch T., Liu Y., Chai W., et al. Receptor-binding specificity of pandemic influenza A (H1N1) 2009 virus determined by carbohydrate microarray. Nat Biotechnol 2009, 27(9):797-799.
9. Wei C.J., Boyington J.C., Dai K., et al. Cross-neutralization of 1918 and 2009 influenza viruses: role of glycans in viral evolution and vaccine design. Sci transl Med 2010, 2(2': 24):ra21.
10. Xu R., Ekiert D.C., Krause J.C., Hai R., Crowe J.E., Wilson I.A. Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science 2010, 328:357-360.
11. Manicassamy B., Medina R.A., Hai R., Tsibane T., Stertz S., Nistal-Villan E., et al. Protection of mice against lethal challenge with 2009 H1N1 influenza A virus by 1918-like and classical swine H1N1 based vaccines. PLoS Pathog 2010, 6:e1000745.
12. Cohen J. Swine flu pandemic, What's old is new: 1918 virus matches 2009 H1N1 strain. Science 2010, 327:1563-1564.
13. Greenberg M.E., Lai M.H., Hartel G.F., Wichems C.H., Gittleson C., Bennet J., et al. Response to a 2009 monovalent influenza A (H1N1) vaccine. N Engl J Med 2009, 361:2405-2413.
14. Plennevaux E., Sheldon E., Blatter M., Reeves-Hoche M.K., Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 2010, 375:41-48.
15. Liang X.F., Wang H.Q., Wang J.Z., Fang H.H., Wu J., Zhu F.C., et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2010, 375:56-66.
16. Zhu F.C., Wang H., Fang H.H., Yang J.G., Lin X.J., Liang X.F., et al. A novel Influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009, 361:2414-2423.
17. Clark T.W., Pareek M., Hoschler K., Dillon H., Nicholson K.G., Groth N., et al. Trial of 2009 Influenza A (H1N1) Monovalent MF59-adjuvanted vaccine. N Engl J Med 2009, 361:2424-2435.
18. Vajo Z., Tamas F., Sinka L., Jankovics I. Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial. Lancet 2010, 375:49-55.
19. Nolan T., McVernon J., Skeljo M., Richmond P., Wadia U., Lambert S., et al. Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial. JAMA 2010, 303:37-46.
20. Girard M.P., Osterhaus A., Pervikov Y., Palkonyay L., Kieny M.P. Report of the third meeting on " influenza vaccines that induce broad spectrum and long-lasting immune responses" , World Health Organization, Geneva, Switzerland, 3-4 December 2007. Vaccine 2008, 26:2443-2450.
21. Roman F., Vaman T., Gerlach B., Markendorf A., Gillard P., Devaster J.M. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 2010, 28(February 17 (7)):1740-1745.
22. Stasakova J., Ferko B., Kittel C., Sereinig S., Romanova J., Kattinger H., et al. Influenza A mutant viruses with altered NS1 protein function provoque caspase-1 activation in primary human macrophages, resulting in fast apoptosis and release of high levels of interleukins 1 beta and 18. J Gen Virol 2005, 86(January (Pt1)):185-195.
23. Huang W.T., Chuangv J.H., Kuo S.H. Monitoring the safety of pandemic H1N1 vaccine. Lancet 2010, 375(April 3):1164.
24. Nicoll A., Ammon A., Amato A., Ciancio B., Zucs P., Devaux I., et al. Experience and lessons from surveillance and studies of the 2009 pandemic in Europe. Public Health 2010 Jan, 124:14-23.
25. Nokleby H., Nicoll A. Risk groups and other target groups-preliminary ECDC guidance for developing influenza vaccination recommendations for the season 2010-11. Euro Surveill 2010, 15(March 25 (12)):19525.
26. http://www.who.int/vaccine_research/diseases/influenza/meeting_18_19Feb2010/en/index.html (consulted on 18 May 2010): The 6th WHO meeting on evaluation of pandemic influenza vaccines in clinical trials, 18-19 February 2010, Geneva, Switzerland.